Market Cap 341.56M
Revenue (ttm) 72.59M
Net Income (ttm) -218.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -301.64%
Debt to Equity Ratio 0.00
Volume 780,300
Avg Vol 488,938
Day's Range N/A - N/A
Shares Out 69.71M
Stochastic %K 91%
Beta 1.56
Analysts Strong Sell
Price Target $12.33

Company Profile

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expr...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 1223 261 503
Address:
Portway Building, Blocks A & B Granta Park Great Abington, Cambridge, United Kingdom
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 30 at 1:51 PM
$BCYC I think the selling here is overdone. Cash runway into 2030. Market cap << cash. Nice platform. If anything works out (which I believe it should) a seriour repricing will follow
1 · Reply
aquira
aquira Apr. 30 at 1:43 PM
$BCYC looks like there is no saving this stock
0 · Reply
mmtiddy
mmtiddy Apr. 28 at 9:20 AM
$BCYC $800 million+ on cash, Phase 1/2 showed promising data 4 out of 10 patients got their tumors reduced And an additional 3 out of 3 patients saw a reduction too who were not exposed to the toxin before I think they will be more of a push for peptides, US media has been pushing for these breakthroughs I think the deprioritizing of their previous lead drug while reduces the value of this company, this is completely oversold The drug did not fail - it just was not feasible when another drug in the market has better results and is from big pharma
1 · Reply
mmtiddy
mmtiddy Apr. 25 at 7:57 PM
$BCYC Give some good news next week on earnings and this can squeeze really good
0 · Reply
mmtiddy
mmtiddy Apr. 23 at 6:11 AM
$BCYC I think this company is massively undervalued, their staff is stacked with pockets of experience everywhere you look financially and scientifically They also on somewhat of a hiring window as well, I see 8 positions opened up the last week on LinkedIn I think something might be brewing here, well financed, and if their new lead candidate has some legs for Phase 2 trial I think this can shoot up past $15 again
0 · Reply
mmtiddy
mmtiddy Apr. 22 at 7:18 PM
$BCYC I am joining on good luck and vibes, a well funded company with some promising catalysts this year
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 22 at 11:12 AM
$BCYC u in the way have also been suppressing u for now
0 · Reply
eladfff
eladfff Apr. 21 at 2:11 PM
$BCYC Again pushing data, again without any explanation (at least publicly). Both long-term Ph1 and detailed dose selection Ph 2/3 data for zelenectide was repeatedly promised "at a scientific conference in 1H26". This is after both were previously pushed from 2H25. Now it's AGAIN pushed to 2H26. Execs are completely untrustworthy and unreliable. Not surprising that this is trading with an extreme negative value (subtracting cash). Dishonest management and 4+ years of spinning wheels with BDCs and going absolutely nowhere. Have very little to show for years of time and money. What exactly do you do here, Kevin Lee and team?
1 · Reply
PrayTradeRepeat
PrayTradeRepeat Apr. 19 at 3:58 PM
$BCYC The conference started April 17. Data is coming out right now. What we have so far is simple. Drug looks safe. Some early signs it might be working. Nothing game changing yet. This is early data. That means potential, not proof. Peptide hype from the White House sounds good but that doesn’t automatically mean revenue here. Two separate things. This is a catalyst trade. Watch volume. Watch reaction at resistance. If it breaks clean, it can move. If it stalls, it gets sold. Trade it. Don’t marry it.
0 · Reply
PrayTradeRepeat
PrayTradeRepeat Apr. 19 at 3:54 PM
$BCYC PEPTIDE FOMO IN LAST 24 HOURS IS INSANE. WATCH THIS MONDAY.
0 · Reply
Latest News on BCYC
Bicycle Therapeutics Transcript: Status Update

Dec 13, 2024, 8:00 AM EST - 1 year ago

Bicycle Therapeutics Transcript: Status Update


Bicycle Therapeutics Transcript: Status Update

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Bicycle Therapeutics Transcript: Status Update


Bicycle Therapeutics Transcript: R&D Day 2023

Dec 14, 2023, 8:00 AM EST - 2 years ago

Bicycle Therapeutics Transcript: R&D Day 2023


Bicycle Therapeutics to Host R&D Day on December 14

Nov 30, 2023, 7:00 AM EST - 2 years ago

Bicycle Therapeutics to Host R&D Day on December 14


Bicycle Therapeutics Transcript: Study Update

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Bicycle Therapeutics Transcript: Study Update


Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 30 at 1:51 PM
$BCYC I think the selling here is overdone. Cash runway into 2030. Market cap << cash. Nice platform. If anything works out (which I believe it should) a seriour repricing will follow
1 · Reply
aquira
aquira Apr. 30 at 1:43 PM
$BCYC looks like there is no saving this stock
0 · Reply
mmtiddy
mmtiddy Apr. 28 at 9:20 AM
$BCYC $800 million+ on cash, Phase 1/2 showed promising data 4 out of 10 patients got their tumors reduced And an additional 3 out of 3 patients saw a reduction too who were not exposed to the toxin before I think they will be more of a push for peptides, US media has been pushing for these breakthroughs I think the deprioritizing of their previous lead drug while reduces the value of this company, this is completely oversold The drug did not fail - it just was not feasible when another drug in the market has better results and is from big pharma
1 · Reply
mmtiddy
mmtiddy Apr. 25 at 7:57 PM
$BCYC Give some good news next week on earnings and this can squeeze really good
0 · Reply
mmtiddy
mmtiddy Apr. 23 at 6:11 AM
$BCYC I think this company is massively undervalued, their staff is stacked with pockets of experience everywhere you look financially and scientifically They also on somewhat of a hiring window as well, I see 8 positions opened up the last week on LinkedIn I think something might be brewing here, well financed, and if their new lead candidate has some legs for Phase 2 trial I think this can shoot up past $15 again
0 · Reply
mmtiddy
mmtiddy Apr. 22 at 7:18 PM
$BCYC I am joining on good luck and vibes, a well funded company with some promising catalysts this year
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 22 at 11:12 AM
$BCYC u in the way have also been suppressing u for now
0 · Reply
eladfff
eladfff Apr. 21 at 2:11 PM
$BCYC Again pushing data, again without any explanation (at least publicly). Both long-term Ph1 and detailed dose selection Ph 2/3 data for zelenectide was repeatedly promised "at a scientific conference in 1H26". This is after both were previously pushed from 2H25. Now it's AGAIN pushed to 2H26. Execs are completely untrustworthy and unreliable. Not surprising that this is trading with an extreme negative value (subtracting cash). Dishonest management and 4+ years of spinning wheels with BDCs and going absolutely nowhere. Have very little to show for years of time and money. What exactly do you do here, Kevin Lee and team?
1 · Reply
PrayTradeRepeat
PrayTradeRepeat Apr. 19 at 3:58 PM
$BCYC The conference started April 17. Data is coming out right now. What we have so far is simple. Drug looks safe. Some early signs it might be working. Nothing game changing yet. This is early data. That means potential, not proof. Peptide hype from the White House sounds good but that doesn’t automatically mean revenue here. Two separate things. This is a catalyst trade. Watch volume. Watch reaction at resistance. If it breaks clean, it can move. If it stalls, it gets sold. Trade it. Don’t marry it.
0 · Reply
PrayTradeRepeat
PrayTradeRepeat Apr. 19 at 3:54 PM
$BCYC PEPTIDE FOMO IN LAST 24 HOURS IS INSANE. WATCH THIS MONDAY.
0 · Reply
PrayTradeRepeat
PrayTradeRepeat Apr. 18 at 8:35 PM
$BCYC WILL RUN MONDAY https://www.tiktok.com/t/ZP8gm3W3e/
0 · Reply
dgbio
dgbio Apr. 18 at 10:14 AM
$BCYC 'BT5528 + nivo demonstrated a generally well-tolerated safety profile across doses, with no new safety signals, in contrast to prior attempts to target EphA2, with no PK drug-drug interactions. Preliminary anti-tumor activity was demonstrated in pts with mUC at a dose of BT5528 6.5 mg/m2 once every 2 wks + nivo 480 mg once every 4 wks, especially in MMAE-naive pts with EphA2+ tumors'. https://aacrjournals.org/cancerres/article/86/8_Supplement/CT063/783018/Abstract-CT063-An-EphA2-targeting-Bicycle-Drug?searchresult=1
1 · Reply
TangibleOne
TangibleOne Apr. 18 at 3:36 AM
$BCYC loaded with my shares here and just took a position with SKM (ticker) for the Anthropic pre IPO exposure! 🤑🤑🤑
0 · Reply
dgbio
dgbio Apr. 18 at 3:16 AM
$BCYC 'Expression of EphA2 was found in all PDAC PDX models. Most models were sensitive to BT5528 treatment, which was not affected by the degree of desmoplasia or membrane EphA2 TPS. These results may reflect a lack of truly EphA2-negative models in this analysis. These data support the potential for BT5528 to offer a novel option for the treatment of PDAC'. https://aacrjournals.org/cancerres/article/86/7_Supplement/4518/777762/Abstract-4518-Preclinical-assessment-of-BT5528?searchresult=1
0 · Reply
dgbio
dgbio Apr. 18 at 3:14 AM
$BCYC 'BT5528 has shown potent preclinical anti-tumor activity in EphA2-expressing CDX models of HNSCC at clinically relevant doses. These data support the potential to further evaluate BT5528 in HNSCC'. https://aacrjournals.org/cancerres/article/86/7_Supplement/1325/777503/Abstract-1325-Preclinical-assessment-of-BT5528?searchresult=1
0 · Reply
dgbio
dgbio Apr. 18 at 3:12 AM
$BCYC 20-30% of all breast cancers have high NECTIN4 copy numbers. 'NECTIN4 amplification is frequent, concordant with high RNA and protein expression, and stable in frequency between primary and metastatic BC. Nectin-4 can be effectively engaged by the BDC zelenectide pevedotin with high affinity. The frequency and stability of NECTIN4 amplification across breast cancer subtypes supports its evaluation as a biomarker for patient selection in Nectin-4-targeted trials'. https://aacrjournals.org/cancerres/article/86/7_Supplement/7227/781330/Abstract-7227-NECTIN4-amplified-breast-cancer?searchresult=1
0 · Reply
PrayTradeRepeat
PrayTradeRepeat Apr. 17 at 2:08 PM
$EFOI Trading this LIVE NOW $IXHL $LAES $BCYC Pray Day Trade Repeat , Closed over $1K already https://youtube.com/live/f24t9FkkHwM?feature=share
0 · Reply
kubota2323
kubota2323 Apr. 14 at 3:25 PM
$BCYC adding a few bags
0 · Reply
Old_Bag
Old_Bag Apr. 13 at 6:45 PM
1 · Reply
PrayTradeRepeat
PrayTradeRepeat Apr. 13 at 6:10 PM
0 · Reply
PrayTradeRepeat
PrayTradeRepeat Apr. 13 at 5:32 PM
$BCYC $IXHL $LAES $RMSG This was a perfect set up.
0 · Reply
PrayTradeRepeat
PrayTradeRepeat Apr. 13 at 12:14 PM
$RMSG DAY TRADE REPEAT ALARM: $RMSG Premarket ran from 0.45 to 0.99 That’s a 100% move off the lows This is momentum, not fundamentals 10.9M shares outstanding CEO controls ~65.8% Class B = 10x voting power Tight, controlled float March 25 deal CEO funded $1.08M Bought 1,837,680 shares at $0.5912 That’s your anchor Financials: Cash $846K Equity $1.1M (below Nasdaq min) Revenue $25K Net loss $2.38M in 6 months Burn $1.5M / 6 months Accumulated deficit ~$22.5M “Going concern” risk They need funding Nasdaq deficiency Have 45 days to fix Likely: Dilution Share issuance Reverse split Levels: 0.59 insider anchor 1.00 breakout 1.20–1.50 sell zone This is a trade Not a hold No revenue Burning cash Will need to raise It can run But every spike = potential selling Trade it Don’t get stuck $IXHL $LAES $BCYC
0 · Reply